Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)
Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)
复制标题
DOI：
10.2460/javma.237.9.1052
复制
发表时间：
2010-11-01
影响因子：
1.9
通讯作者：
Klein, Mary K.
中科院分区：
文献类型：
--
作者：
Beaver, Lynda M.;Strottner, Gabriele;Klein, Mary K.
目的：确定单剂阿霉素治疗B细胞或T细胞多中心淋巴瘤或胸腺淋巴瘤后的有效率。设计-回顾性病例系列。动物-41只客户所有的淋巴瘤。过程-2006年2月至2008年10月诊断为淋巴瘤的犬的医疗记录。入选标准包括确认患有淋巴瘤，免疫表型为B细胞或T细胞来源。只有那些只接受阿霉素作为第一次化疗并在一周后接受评估的狗才被纳入研究。当狗之前接受了皮质类固醇治疗时，它们被排除在外。回顾病历，以获得淋巴瘤的信号、分期和亚期，以及免疫表型，并确定诊断时狗是否有高钙血症。结果：T细胞淋巴瘤犬对阿霉素的应答率显著低于B细胞淋巴瘤犬。患有B细胞淋巴瘤的29只狗中有25只(86.2%)有完全反应，而T细胞组的12只狗中有2只有完全反应。B细胞淋巴瘤的总有效率为100%，而T细胞淋巴瘤的总有效率为50%。结论阿霉素是治疗犬淋巴瘤的临床相关性和标准化疗方案。许多患有T细胞淋巴瘤的狗对阿霉素没有反应；因此，包含阿霉素的多药方案可能不是最佳方案。对于对阿霉素无效的T细胞淋巴瘤的狗，应该考虑使用替代方案。(兽医协会杂志2010；237：1052-1055)
Objective-To determine the response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell multicentric or thymic lymphoma.Design-Retrospective case series.Animals-41 client-owned dogs with lymphoma.Procedures-Medical records of dogs in which lymphoma was diagnosed between February 2006 and October 2008 were reviewed. Entry criteria included that dogs had a confirmed lymphoma that was immunophenotyped to be of B-cell or T-cell origin. Only dogs that received doxorubicin alone as their first chemotherapy treatment and were evaluated 1 week later were included in the study. Dogs were excluded when they had received prior treatment with corticosteroids. Medical records were reviewed to obtain signalment, stage and substage of lymphoma, and immunophenotype and to determine whether the dog had hypercalcemia at the time of diagnosis.Results-Dogs with T-cell lymphoma had a significantly lower response rate to doxorubicin than did dogs with B-cell lymphoma. Twenty-five of 29(86.2%) dogs with B-cell lymphoma had a complete response, compared with 2 of 12 dogs in the T-cell group that had a complete response. The overall response rate of dogs with B-cell lymphoma was 100%, compared with a response rate of 50% in dogs with T-cell lymphoma.Conclusionsand Clinical Relevance-Standard-of-care chemotherapy protocols for the treatment of dogs with lymphoma include doxorubicin. Many dogs with T-cell lymphoma did not respond to doxorubicin; therefore, multiagent protocols containing doxorubicin may not be optimal. Alternative protocols should be considered for dogs with T-cell lymphoma that do not respond to doxorubicin. (J Am Vet Med Assoc 2010;237:1052-1055)